S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
From -60% Account to Doubling His Money? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
From -60% Account to Doubling His Money? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
From -60% Account to Doubling His Money? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
From -60% Account to Doubling His Money? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:BLUE

bluebird bio (BLUE) Stock Forecast, Price & News

$3.63
+0.09 (+2.54%)
(As of 06/2/2023 ET)
Compare
Today's Range
$3.40
$3.64
50-Day Range
$2.79
$5.03
52-Week Range
$2.78
$8.58
Volume
3.54 million shs
Average Volume
3.70 million shs
Market Capitalization
$386.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

bluebird bio MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
92.8% Upside
$7.00 Price Target
Short Interest
Bearish
22.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of bluebird bio in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.13) to ($1.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

407th out of 983 stocks

Biological Products, Except Diagnostic Industry

64th out of 164 stocks


BLUE stock logo

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

Barclays Upgrades bluebird bio (NASDAQ:BLUE) to Overweight
Baird analysts unfazed by bluebird bio short sellers
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
bluebird bio shortseller attack leaves analysts unfazed
The Latest Analyst Ratings for bluebird bio
Positive Report for Bluebird Bio (BLUE) from Barclays
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Vor Biopharma (VOR) Receives a Buy from Robert W. Baird
RBC Capital Sticks to Its Hold Rating for Bluebird Bio (BLUE)
SVB Securities Keeps Their Hold Rating on Bluebird Bio (BLUE)
Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates
What Wall Street expects from bluebird bio's earnings
bluebird bio (BLUE) Scheduled to Post Earnings on Tuesday
See More Headlines

BLUE Price History

BLUE Company Calendar

Last Earnings
5/09/2023
Today
6/03/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
518
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+92.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$-266,580,000.00
Net Margins
-3,054.45%
Pretax Margin
-3,051.55%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$3.33 per share

Miscellaneous

Free Float
103,326,000
Market Cap
$386.27 million
Optionable
Optionable
Beta
0.89

Key Executives

  • Nick LeschlyNick Leschly
    Director
  • Andrew ObenshainAndrew Obenshain
    President, Chief Executive Officer & Director
  • Thomas J. Klima
    Chief Operating & Commercial Officer
  • Christopher Stanley Krawtschuk
    Chief Financial Officer
  • Richard Colvin
    Chief Medical Officer













BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price forecast for 2023?

10 equities research analysts have issued 1 year target prices for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they predict the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 92.8% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2023?

bluebird bio's stock was trading at $6.92 on January 1st, 2023. Since then, BLUE shares have decreased by 47.5% and is now trading at $3.63.
View the best growth stocks for 2023 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Tuesday, May, 9th. The biotechnology company reported $0.21 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.75. The biotechnology company had revenue of $2.40 million for the quarter, compared to analysts' expectations of $26.97 million. bluebird bio had a negative net margin of 3,054.45% and a negative trailing twelve-month return on equity of 52.40%. The company's revenue for the quarter was up 26.3% on a year-over-year basis. During the same quarter last year, the business earned ($1.66) EPS.

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (16.70%), BlackRock Inc. (8.41%), Pictet Asset Management SA (2.92%), Dimensional Fund Advisors LP (2.44%), Geode Capital Management LLC (1.97%) and Bank of America Corp DE (1.85%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $3.63.

How much money does bluebird bio make?

bluebird bio (NASDAQ:BLUE) has a market capitalization of $386.27 million and generates $3.60 million in revenue each year. The biotechnology company earns $-266,580,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does bluebird bio have?

The company employs 518 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -